Clinical-epidemiological characteristics and surveillance in monitoring SARS-CoV-2 in the municipality of Teresopolis, RJ, Brazil
DOI:
https://doi.org/10.33448/rsd-v11i14.34415Keywords:
Health Surveillance; SARS-CoV-2; Clinical-epidemiological profile.Abstract
The high transmissibility of SARS-CoV-2 can be attributed to the unique virological characteristics of SARS-CoV-2. Early diagnosis is crucial to controlling the spread of SARS-CoV-2. The most common cardiovascular problems in patients with SARS-CoV-2 is acute myocardial injury. However, SARS-CoV-2 can cause direct and indirect cardiovascular sequelae, including acute coronary syndromes, cardiomyopathy, acute cor pulmonale, arrhythmias, and cardiogenic shock. Thus, as the disease progresses, there is a need for new clinical evidence based on epidemiological data and laboratory findings, and it is prudent to identify risk factors for the development of systemic complications associated with disease severity and may predict worse clinical outcomes. and increased mortality. The objective of the research is to evaluate and describe the clinical and epidemiological profile of SARS-CoV-2 cases, in order to assess the sociodemographic, clinical and epidemiological characteristics of individuals, seeking to subsidize the panorama of the spread of the disease, protection of the population through vaccination. , as well as the prevalence of diagnoses resulting from the virus in the city of Teresópolis - RJ, to assist in the understanding of the disease and its effects, so that solutions can be sought.
References
Belouzard, S. J. K., Millet, B. N., & Licitra, G. R. (2012). Whittaker Mechanisms of coronavirus cell entry mediated by the viral spike protein Viruses, 4 (6), pp. 1011-1033, 2012
Brasil. (2022) Ministério da Saúde. Diretrizes Estratégicas n.d. https://bvsms.saude.gov.br/bvs/pacsaude/diretrizes.php
Brasil. (2003). Ministério da Saúde. Programa Nacional de Imunizações - 30 anos/Ministério da Saúde, Secretaria de Vigilância em Saúde – Brasília. https://bvsms.saude.gov.br/bvs/publicacoes/livro_30_anos_pni.pdf
Brasil. (2020). Ministério da Saúde. Centro de Operações de Emergências em Saúde Pública. Coronavirus SARS-CoV-2. Boletim Diário [Internet]. Brasília (DF): Ministério da Saúde. https://www.saude.gov.br/images/pdf/2020/marco/29/29----COVID.pdf
Bustin, S. A. Nolan T. (2020) rt-qPCR testing of SARS-CoV-2: a primer Int J Mol Sci, 21 (8), p. 3004
Chen, H., et al (2020). Clinical characteristics and intrauterine vertical transmission potential of SARS-COV-2 infection in nine pregnant women: a retrospective review of medical records. Lancet 395, 809–815,
Cheng, M. H., et al. (2021). Impact of South African 501.V2 Variant on SARS-CoV-2 spike Infectivity and neutralization: a structure-based computational assessment. bioRxiv, p.
De Toniasso, S. C. C. F. S., Fernandes, D. J., et al (2021). Reduction in SARS-COV-2 prevalence in healthcare workers in a university hospital in southern Brazil after the start of vaccination Int J Infect Dis, 109, pp. 283-285
Deng, S. Q., & Peng, H. J. (2020). Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J. Clin. Med. 9, 575
Ferretti, L. C., Wymant, M., Kendall, L., Zhao, A., Nurtay, L., Abeler-Dörner, M., Parker, D., & Bonsall, C. F. (2020). Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing Science, 368, p. eabb6936
Hallal, P. C., Hartwig, F. P., Horta, B. L., Silveira, M. F., Struchiner, C. J., Vidaletti, L. P., et al. (2021). SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys Lancet Glob. Health, 8 (11), pp. e1390-e1398
Han, Q., Lin, Q., Jin, S., & You, L. (2020). Coronavirus 2019-nCoV: a brief perspective from the front line. J. Infect. 80, 373–377
Hellewell, J. S., Abbott, A., & Gimma, N. I. (2020) Eggo Feasibility of controlling SARS-COV-2 outbreaks by isolation of cases and contacts Lancet Glob. Heal., 8, pp. e488-e496,
Huang, C. Y., Wang, X., Li, L., Ren, J., Zhao, Y. H., et al. (2020). Novel coronavirus in Wuhan, China Lancet, 395, pp. 497-506
Hui, D. S., et al. (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Intl. J. Infect. Dis. 91, 264–266,
Instituto Butantã. (2020) Projeto S: imunização em serrana faz casos de SARS-CoV-2 despecarem 80% e mortes, 95%. https://butantan.gov.br/noticias/projeto-s-imunizacao-em-serrana-faz-casos-de-SARS-CoV-2-despencarem-80-e-mortes-95
Lee, J. S. S., Park, H. W., Jeong, J. Y., Ahn, S. J., Choi, H. L., et al. (2020) Immunophenotyping of SARS-COV-2 and influenza highlights the role of type I interferons in development of severe SARS-COV-2 Sci Immunol, 5 (49)
Li, B., Yang, J., Zhao, F., et al. (2020). Prevalence and impact of cardiovascular metabolic diseases on SARS-COV-2 in China. Clin Res Cardiol 109:531–538,
Li, W. M. J., Moore, N., Vasilieva, J., Sui, S. K., & Wong, M. A. B, et al. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Nature, 426, pp. 450-454
Lu, X., et al. (2020). SARS-CoV-2 infection in children. N. Engl. J. Med. 382, 1663–1665
Pasrija, R. M. (2021). Naime The deregulated immune reaction and cytokines release storm (CRS) in SARS-COV-2 disease Int Immunopharmacol, 90, Article 107225,
Puranik, A. P., Lenehan, E., Silvert, M. J., Niesen, J., Corchado-Garcia, J. C., O’horo, et al. (2021). Comparison of Two Highly-Effective mRNA Vaccines for SARS-COV-2 During Periods of Alpha and Delta Variant Prevalence SSRN Electron. J., 2, 1-29
Ragab, D. H., Salah ELDIN, M., Taeimah, R., & Khattab, R. (2020) Salem The SARS-COV-2 cytokine storm; what we know so far Front Immunol, 11, p. 1446,
Rahimi, A. A., & Mirzazadeh, S (2020) Tavakolpour Genetics and genomics of SARS-CoV-2: a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection Genomics, Epub ahead of print
Rai, P., Kumar, B. K. V. K., Deekshit, I., Karunasagar, I., Karunasagar. (2021). Detection technologies and recent developments in the diagnosis of SARS-COV-2 infection. Appl. Microbiol. Biotechnol., 105 (2), 441-455
Ramesh, S. M., Govindarajulu, R. S., Parise, L., Neel, T., Shankar, S., Patel, et al. (2021). Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy Vaccines (Basel), 9, 1195,
Shang, J. Y., Wan, C., Luo, G., Ye, Q., Geng, A., Auerbach, et al. (2020). Cell entry mechanisms of SARS-CoV-2 Proc Natl Acad Sci USA, 117 (21), 11727-11734
Struyf, T. J. J., Deeks, J. D., et al. (2021). Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has SARS-COV-2 Cochrane Database of Systematic Reviews (2),
Tang, Y. J., Liu, D., Zhang, Z., Xu, J., & JI, C. W. (2020). Cytokine storm in SARS-COV-2: the current evidence and treatment strategies Front Immunol, 11, 1708,
Vasileiou, E. C. R., & Simpson, C. R., et al. (2021). Effectiveness of first dose of SARS-COV-2 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people SSRN,
Vasileiou, E. C. R., Simpson, T., Shi, S., Kerr, U. A., et al. (2021). Interim findings from first-dose mass SARS-COV-2 vaccination roll-out and SARS-COV-2 hospital admissions in Scotland: a national prospective cohort study The Lancet, 397 (10285), 1646-1657
Victora, C. M. C., Castro, S., Gurzenda, A. C., Medeiros, G. V. A., & França, A. J. D. (2021). Estimating the early impact of vaccination against SARS-COV-2 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality EClinicalMedicine, 38, Article 101036
Wang, S. T.Q., Le, N., Kurihara, J., Chida, Y., Cisse, M. Y., et al. (2010). Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza J Infect Dis, 202, 991-1001
Wibmer, C. K., et al. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African SARS-COV-2 donor plasma bioRxiv,
World Health Organization (2020). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (SARS-COV-2). Geneva (Switzerland): World Health Organization;. https://www.who.int/docs/default-source/coronaviruse/who-chinajoint-mission-on-SARS-CoV-2-final-report.pdf
World Health Organization (WHO). (2020). Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance [Internet]. Geneva: WHO; 2020. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf
Wu, J. T., Leung, K., & Leung, G. M. (2020). Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395, 689–697,
Wu, Z., & Mcgoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (SARS-COV-2) outbreak in china: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 1239–1242
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Victor Hugo da Costa Palatnic; Sandro Pinheiro da Costa; Ketllyn de Azevedo Machado; Ana Alaide Ferreira de Almeida; Lucas Padrão de Oliveira Zambrotti; Tainara Calgaro Rei; Maria Eduarda do Nascimento Bulhões; Carina Dias Ferreira de Andrade; Tayná Livia do Nascimento; Renata Pereira de Azevedo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
